Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.000
-0.040 (-1.32%)
At close: Aug 13, 2025, 4:00 PM
3.050
+0.050 (1.67%)
After-hours: Aug 13, 2025, 4:10 PM EDT
Anixa Biosciences Employees
As of October 31, 2024, Anixa Biosciences had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,426,800
Market Cap
97.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANIX News
- 1 day ago - Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - PRNewsWire
- 5 days ago - Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - PRNewsWire
- 9 days ago - Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial - PRNewsWire
- 14 days ago - Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 20 days ago - Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s - PRNewsWire
- 4 weeks ago - Anixa Biosciences: Oncology Platform With Asymmetric Upside - Seeking Alpha
- 5 weeks ago - Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology - PRNewsWire
- 7 weeks ago - Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire